Skip to main content

SR

Stock
Utilities
Utilities - Regulated Gas

Performance overview

SR Price
Price Chart

Forward-looking statistics

Beta
Risk

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

life at spire has many facets, but there is one common thread — our energy. at spire, public service is our daily business. that’s why we’re always looking for driven, collaborative people to join our team. because we believe that offering our customers the best service means bringing the best people together. from missouri to alabama and beyond, our employees are here to help their communities grow. that’s what we encourage because that’s what leads to success for our customers and our business.

Company info

SectorUtilities
IndustryUtilities - Regulated Gas
Employees2K
Market cap$3.4B

Fundamentals

Enterprise value$9.3B
Revenue$2.4B
Revenue per employee
Profit margin10.38%
Debt to equity135.55

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$3.91
Dividend per share$3.14
Revenue per share$42.01
Avg trading volume (30 day)$34M
Avg trading volume (10 day)$37M
Put-call ratio

Macro factor sensitivity

Growth+1.0
Credit+2.1
Liquidity+0.1
Inflation-2.0
Commodities-0.1
Interest Rates-0.1

Valuation

Dividend yield4.26%
PEG Ratio16.24
Price to sales1.80
P/E Ratio16.24
Enterprise Value to Revenue3.83
Price to book1.34

Upcoming events

Next earnings dayApril 30, 2025
Next dividend day
Ex. dividend dayJune 11, 2025

News

SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program

Sarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.

Zacks Investment Research (July 21, 2025)
BMO's Kostas Biliouris: It will be challenging for the FDA to force a market withdrawal for Sarepta

Kostas Biliouris, BMO Capital Markets biotech analyst, joins CNBC's 'Squawk on the Street' to discuss the latest details on Sarepta after the company declined the FDA's request to halt shipments of its gene therapy.

CNBC Television (July 21, 2025)
Sierra Bancorp (BSRR) Earnings Expected to Grow: Should You Buy?

Sierra Bancorp (BSRR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research (July 21, 2025)
Sarepta Therapeutics: Why Is SRPT Stock Crashing?

Sarepta Therapeutics has plunged to new lows below $13, down over 35% in recent trading, after rejecting the FDA's request to voluntarily halt all shipments of Elevidys following a third death tied to the gene therapy. Just days after our previous analyses highlighted the company's apparent undervaluation following its restructuring, its defiant stance has now triggered fresh investor concerns, validating the regulatory risks associated with biotech stocks.

Forbes (July 21, 2025)
Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys

The ground shook for Sarepta Therapeutics, Inc. SRPT last week as the U.S. Food and Drug Administration (FDA), alarmed by a third patient death tied to its gene therapy platform, pulled a rare move: requesting a voluntary halt to Elevidys shipments. The company's response?

Benzinga (July 21, 2025)
Sarepta shares plunge 30% as future of its gene therapy appears at risk

Shares of Sarepta Therapeutics plunged more than 30% on Friday after Food and Drug Administration Commissioner Marty Makary said the agency is considering whether the company's gene therapy should stay on the market. Sarepta has reported three patient deaths related to its gene therapies.

CNBC (July 18, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free